المؤلفون: Le Goff, Enora, Blanc‐durand, Paul, Roulin, Louise, Lafont, Charlotte, Loyaux, Romain, Mboumbae, Diana‐laure, Benmaad, Ichrafe, Claudel, Alexis, Poullot, Elsa, Robe, Cyrielle, Gricourt, Guillaume, Aissat, Abdelrazak, Copie‐bergman, Christiane, Lemonnier, François, Gaulard, Philippe, Itti, Emmanuel, Haioun, Corinne, Delfau‐larue, Marie‐helene

المساهمون: Hôpital Henri Mondor, Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), CHU Henri Mondor Créteil, Département de pathologie Mondor, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)

المصدر: ISSN: 0007-1048.

مصطلحات موضوعية: circulating tumour DNA, neoplasm staging, non-Hodgkin lymphoma, positron emission tomography computed tomography, prognosis, [SDV.CAN]Life Sciences [q-bio]/Cancer

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/37038217; hal-04134838; https://hal.u-pec.fr/hal-04134838Test; https://hal.u-pec.fr/hal-04134838/documentTest; https://hal.u-pec.fr/hal-04134838/file/Br%20J%20Haematol%20-%202023%20-%20Le%20Goff%20-%20Baseline%20circulating%20tumour%20DNA%20and%20total%20metabolic%20tumour%20volume%20as%20early%20outcome.pdfTest; PUBMED: 37038217

الإتاحة: https://doi.org/10.1111/bjh.18809Test
https://hal.u-pec.fr/hal-04134838Test
https://hal.u-pec.fr/hal-04134838/documentTest
https://hal.u-pec.fr/hal-04134838/file/Br%20J%20Haematol%20-%202023%20-%20Le%20Goff%20-%20Baseline%20circulating%20tumour%20DNA%20and%20total%20metabolic%20tumour%20volume%20as%20early%20outcome.pdfTest

المؤلفون: Pascual, Javier, Attard, Gerhardt, Bidard, François Clément, Curigliano, Giuseppe, de Mattos-Arruda, Leticia, Diehn, Maximilian, Italiano, Antoine, Lindberg, Johan F., Merker, Jason D., Montagut, Clara, Normanno, Nicola, Pantel, Klaus, Pentheroudakis, George, Popat, Sanjay, Reis-Filho, Jorge Sérgio, Tie, Jeanne, Seoane, Joan, Tarazona, Noelia, Yoshino, Takayuki, Turner, Nicholas C.

المساهمون: Université de Versailles Saint-Quentin-en-Yvelines - UFR Sciences de la santé Simone Veil (UVSQ Santé), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Institut Curie Paris, Département d’Innovation Thérapeutique et essais précoces Gustave Roussy (DITEP), Institut Gustave Roussy (IGR), Université de Bordeaux (UB), Institut Bergonié Bordeaux, UNICANCER, National Institutes of Health, NIH, American Association for Cancer Research, AACR, National Cancer Institute, NCI: 1-UG1-CA233333-01, Boehringer Ingelheim, BI, Mesothelioma Applied Research Foundation, MARF, Amgen, Bristol-Myers Squibb, BMS, Eli Lilly and Company, Pfizer, Philips, Astellas Pharma US, APUS, AstraZeneca, Bayer, Genentech, GlaxoSmithKline, GSK, Merck, Novartis, Roche, Sanofi, European Association for Cancer Research, EACR, Stanford University, SU, International Association for the Study of Lung Cancer, IASLC, Ariad Pharmaceuticals, Celgene, F. Hoffmann-La Roche, Boehringer Ingelheim, Takeda Pharmaceutical Company, TPC, Janssen Pharmaceuticals, Merck KGaA, Merck Sharp and Dohme, MSD, Chugai Pharmaceutical, Association for Molecular Pathology, AMP, ANGLE, Fondazione Beretta, Roche Innovation Center Zurich, RICZ, Daiichi-Sankyo, European Society for Medical Oncology, ESMO, Ipsen, GA reports receipt of honoraria for participation in Advisory Board from Astellas, AstraZeneca, Bayer, Janssen, Novartis, Orion, Pfizer, Sanofi, Sapience, receipt of honoraria as invited speaker from Astellas, AstraZeneca, Janssen, receipt of royalties for licensing fees from Janssen, receipt of institutional research grants from Astellas and Janssen, non-remunerated activities as a PI in Astellas, Janssen, and non-remunerated advisory role in AstraZeneca and Janssen, FCB reports receipt of honoraria for participation in Advisory Board from Archer, BioNTech, Lilly, Novartis, Pfizer, receipt of honoraria to institution for participation in Advisory Board from AstraZeneca, receipt of honoraria as invited speaker from AstraZeneca, Novartis, Pfizer, Roche, Seagen, receipt of honoraria to institution as invited speaker from Pfizer, Sanofi, receipt of honoraria for expert testimony from Hikma, institutional non-financial interest for research as a coordinating PI from AstraZeneca, Pfizer, ProLynx, Saga and Seagen, GC reports receipt of honoraria for participation in Advisory Board from AstraZeneca, Bristol Myers Squibb (BMS), Daiichi Sankyo, Ellipsis, Exact Sciences, Lilly, Merck, Pfizer, Roche, Veracyte, receipt of honoraria as invited speaker from AstraZeneca, Daiichi Sankyo, Novartis, Pfizer, Roche, receipt of honoraria for writing engagement from Pfizer, institutional research grant for investigator initiated clinical trial from Merck, institutional funding for conduct of phase I studies from Astellas, AstraZeneca, Blueprint Medicine, BMS, Daiichi Sankyo, Kymab, Novartis, Philogen, Roche, Sanofi, non-remunerated activities as an officer of the Italian National Health Council—Advisor for Ministry of Health, non-remunerated advisory role as a member of the Scientific Council of Europa Donna, non-remunerated advisory role in Fondazione Beretta, and non-remunerated member of Board of Directors of the Lega Italiana Lotta ai Tumori, LDMA reports receipt of honoraria as invited speaker, participation in speaker bureau from Roche, institutional research collaboration grant from NanoString and receipt of education grant from BMS, MD reports receipt of honoraria for participation in Advisory Board from AstraZeneca, Boehringer Ingelheim, Genentech, Gritstone Oncology, Illumina, receipt of honoraria for consultancy from BioNTech, Novartis, RefleXion, Roche, has ownership interest with CiberMed, Foresight Diagnostics, receipt of royalties for licensing fees from Foresight Diagnostics, Roche Diagnostics, receipt of institutional financial interest as a coordinating PI from AstraZeneca, Varian, receipt of funding from Genentech, non-financial interest for receipt of reagents from Illumina, non-remunerated activities as a member of Board of Directors of Foresight Diagnostics, AI reports receipt of honoraria for participation in Advisory Board from Bayer, Chugai Pharmaceutical Co, GlaxoSmithKline, Philips, Roche, institutional non-financial interest as a coordinating PI from AstraZeneca, Bayer, Ipsen, Merck, Merck Sharp & Dohme (MSD) and Roche, JL reports receipt of honoraria to institution as invited speaker from Roche, JDM reports receipt of honoraria for participation in Advisory Board from Illumina, BMS, receipt of honoraria for consultancy from PierianDx, receipt of royalties for licensing fees administered by Stanford University from the United States Patent Office, non-remunerated activities as a member of Board of Directors of the Association for Molecular Pathology, non-remunerated leadership role as a Chair of the Informatics Subdivision of the Association for Molecular Pathology, non-remunerated leadership role as a Vice Chair of the CLSI MM23—Molecular Diagnostic Methods for Solid Tumors Committee of the Clinical and Laboratory Standards Institute (CLSI), non-remunerated activities in the US NIH/NCI as a PI for the NIH 1-UG1-CA233333-01, UNITS: The UNC/UT National Clinical Trials Network Group Integrated Translational Science Production and Consultation Center, CM reports receipt of honoraria for participation in Advisory Board from Biocartis, Merck Serono, receipt of honoraria as invited speaker from Amgen, Guardant Health, Merck Serono, and Pierre Fabre, Roche, receipt of royalties for licensing fees administered by Institut Investigació Hospital del Mar, NN reports receipt of honoraria for participation in Advisory Board from AstraZeneca, Bayer, Biocartis, Incyte, Novartis, Qiagen, Roche, receipt of honoraria as invited speaker from BMS, Eli Lilly, Illumina, Merck, MSD, Sanofi, Thermo Fisher, receipt of institutional research grants from AstraZeneca, Biocartis, Blueprint, Illumina, Incyte, Merck, Qiagen, Roche, Thermo Fisher, leadership non-remunerated role as a President of the International Quality Network for Pathology (IQN Path) and President of the Italian Cancer Society (SIC), KP reports receipt of honoraria for participation in Advisory Board from MSD, Menarini, Hello Healthcare, Sanofi, receipt of honoraria as invited speaker from Abcam, Ipsen Pharma, Medac, Agena, institutional financial interest from Angle plc, European Liquid Biopsy Society, Böhringer Ingelheim and for participation in IMI JT ID Cancer from EU/IMI Cancer-ID consortium, SP reports receipt of honoraria for participation in Advisory Board from Amgen, AstraZeneca, Bayer, BeiGene, Blueprint, BMS, Boehringer Ingelheim, Daiichi Sankyo, Guardant Health, Janssen, Eli Lilly, Merck KGaA, Novartis, Roche, Takeda, institutional financial interest for research as a coordinating PI from Ariad, Boehringer Ingelheim, Celgene, Daiichi Sankyo, Takeda, Turning Point Therapeutics, as a local PI from AstraZeneca, GlaxoSmithKline, Roche, Trizell, as a sub-investigator from Amgen, MSD, non-remunerated advisory role in ALK Positive UK, International Association for the Study of Lung Cancer, Lung Cancer Europe, Ruth Strauss Foundation, non-remunerated leadership role in the British Thoracic Oncology Group as a Chair of Steering Committee, European Thoracic Oncology Platform as a Foundation Council Member, non-remunerated member of Thoracic malignancy Faculty in the European Society for Medical Oncology, non-remunerated member of Board of Directors in the Mesothelioma Applied Research Foundation, JSRF reports consultancy fees from Goldman Sachs, Repare Therapeutics, Paige.AI and Eli-Lilly, membership of the Board of Directors Group Oncoclinicas, stock ownership of Repare Therapeutics, and honoraria for ad hoc participation in the Scientific Advisory Board of Repare Therapeutics, Paige.AI, Roche Tissue Diagnostics, Novartis, Roche/Genentech, Invicro and Personalis, JT reports consultancy fee from Haystack Oncology, receipt of honoraria for participation in Advisory Board from AstraZeneca, BMS, MSD, Inivata, Pierre Fabre, receipt of honoraria as invited speaker from Merck Serono, Amgen and Servier, JS reports ownership interest as a co-founder of Mosaic Biomedicals SL, member of Board of Directors of Northern Biologics Inc., receipt of institutional research grants from Roche Glycart AG, Mosaic Biomedicals SL, Hoffmann-La Roche Ltd, Northern Biologics Inc., Ridgeline Therapeutics, non-remunerated activities as a member of Board of Directors of Asociación Española Contra el Cáncer and a member of Board of Directors, Secretary General of the European Association for Cancer Research (AACR), TY reports receipt of honoraria as invited speaker from Bayer, Chugai, Eli Lilly, Merck Biopharma, Ono, Taiho, receipt of institutional research grants from Amgen, MSD, Ono, Taiho, receipt of institutional financial interest as a local PI from Chugai, Daiichi Sankyo, MSD, Ono, Parexel International, Sanofi and Sumitomo Dainippon, NT reports receipt of honoraria for participation in Advisory Board from Arvinas, AstraZeneca, BMS, GlaxoSmithKline, Lilly, MSD, Novartis, Pfizer, Repare Therapeutics, Roche/Genentech, Zentalis Pharmaceuticals, institutional funding for research from AstraZeneca, MSD, Pfizer, Roche/Genentech, institutional non-financial interest for provision of material for research from BioRad and for provision of assays from Guardant Health. JS is co-founder of Mosaic Biomedicals and has ownership interests from Mosaic Biomedicals and Northern Biologics and reports receipt of grant/research support from Mosaic Biomedicals, Northern Biologics, Roche/Glycart and Hoffmann la Roche. All other authors have declared no conflicts of interest., This project was funded by the European Society for Medical Oncology (no grant number).

المصدر: ISSN: 0923-7534.

مصطلحات موضوعية: circulating tumour DNA (ctDNA), liquid biopsy, precision medicine, [SDV.CAN]Life Sciences [q-bio]/Cancer

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/35809752; hal-03775791; https://hal.science/hal-03775791Test; https://hal.science/hal-03775791/documentTest; https://hal.science/hal-03775791/file/1-s2.0-S0923753422017215-main.pdfTest; PUBMED: 35809752

الإتاحة: https://doi.org/10.1016/j.annonc.2022.05.520Test
https://hal.science/hal-03775791Test
https://hal.science/hal-03775791/documentTest
https://hal.science/hal-03775791/file/1-s2.0-S0923753422017215-main.pdfTest

المؤلفون: Herbreteau, Guillaume, Vallée, Audrey, Knol, Anne-Chantal, Théoleyre, Sandrine, Quéreux, Gaelle, Frénard, Cécile, Varey, Emilie, Hofman, Paul, Khammari, Amir, Dréno, Brigitte, Denis, Marc

المساهمون: Centre Hospitalier Universitaire de Nantes = Nantes University Hospital (CHU Nantes), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre Hospitalier Universitaire de Nantes = Nantes University Hospital (CHU Nantes)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Centre d’Investigation Clinique de Nantes (CIC Nantes), Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nantes = Nantes University Hospital (CHU Nantes), Institut de Recherche sur le Cancer et le Vieillissement (IRCAN), Université Nice Sophia Antipolis (1965 - 2019) (UNS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UniCA)

المصدر: ISSN: 2072-6694.

مصطلحات موضوعية: melanoma, circulating tumour DNA, BRAF, NRAS, mutation, prognosis, [SDV]Life Sciences [q-bio]

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/32664549; inserm-03683624; https://inserm.hal.science/inserm-03683624Test; https://inserm.hal.science/inserm-03683624/documentTest; https://inserm.hal.science/inserm-03683624/file/cancers-12-01871.pdfTest; PUBMED: 32664549; PUBMEDCENTRAL: PMC7409003

الإتاحة: https://doi.org/10.3390/cancers12071871Test
https://inserm.hal.science/inserm-03683624Test
https://inserm.hal.science/inserm-03683624/documentTest
https://inserm.hal.science/inserm-03683624/file/cancers-12-01871.pdfTest

المؤلفون: Decazes, Pierre, Camus, Vincent, Bohers, Elodie, Viailly, Pierre-Julien, Tilly, Hervé, Ruminy, Philippe, Viennot, Mathieu, Hapdey, Sébastien, Gardin, Isabelle, Becker, Stéphanie, Vera, Pierre, Jardin, Fabrice

المساهمون: Equipe Quantification en Imagerie Fonctionnelle (QuantIF-LITIS), Laboratoire d'Informatique, de Traitement de l'Information et des Systèmes (LITIS), Université Le Havre Normandie (ULH), Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie), Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA)-Université Le Havre Normandie (ULH), Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA), Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), Génomique et Médecine Personnalisée du Cancer et des Maladies Neuropsychiatriques (GPMCND), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)

المصدر: ISSN: 2191-219X ; EJNMMI Research ; https://normandie-univ.hal.science/hal-02971227Test ; EJNMMI Research, 2020, 10 (1), pp.120. ⟨10.1186/s13550-020-00717-y⟩.

مصطلحات موضوعية: Positron emission tomography, B cell malignancies, Diffuse large B cell lymphoma, Hodgkin lymphoma, Circulating tumour DNA, Circulating free DNA, [SDV.CAN]Life Sciences [q-bio]/Cancer, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology

العلاقة: hal-02971227; https://normandie-univ.hal.science/hal-02971227Test; https://normandie-univ.hal.science/hal-02971227/documentTest; https://normandie-univ.hal.science/hal-02971227/file/s13550-020-00717-y.pdfTest

الإتاحة: https://doi.org/10.1186/s13550-020-00717-yTest
https://normandie-univ.hal.science/hal-02971227Test
https://normandie-univ.hal.science/hal-02971227/documentTest
https://normandie-univ.hal.science/hal-02971227/file/s13550-020-00717-y.pdfTest

المؤلفون: Sefrioui, David, Blanchard, France, Toure, Emmanuel, Basile, Paul, Beaussire, Ludivine, Dolfus, Claire, Perdrix, Anne, Paresy, Marianne, Antonietti, Michel, Iwanicki-Caron, Isabelle, Alhameedi, Raied, Lecleire, Stéphane, Gangloff, Alice, Schwarz, Lilian, Clatot, Florian, Tuech, Jean-Jacques, Frébourg, Thierry, Jardin, Fabrice, Sabourin, Jean-Christophe, Sarafan-Vasseur, Nasrin, Michel, Pierre, Di Fiore, Frédéric

المساهمون: Génomique et Médecine Personnalisée du Cancer et des Maladies Neuropsychiatriques (GPMCND), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Rouen, Normandie Université (NU), Génétique du cancer et des maladies neuropsychiatriques (GMFC), Service d'Hépato-Gastroentérologie CHU Rouen, Hôpital Charles Nicolle Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Service de Chirurgie Digestive CHU Rouen, Service d'Oncologie Médicale, CRLCC Haute Normandie-Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), Synergie Lyon Cancer-Platform of Bioinformatics-Gilles Thomas, Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard Lyon -Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre Léon Bérard Lyon -Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Groupe de recherches expérimentales sur l'acte musical (GREAM), Université de Strasbourg (UNISTRA)

المصدر: ISSN: 0007-0920.

مصطلحات موضوعية: CA19.9, pancreatic adenocarcinoma, endoscopic ultrasound-guided fine needle aspiration, circulating tumour cells, circulating tumour DNA, solid pancreatic tumours, [SDV.CAN]Life Sciences [q-bio]/Cancer, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology

العلاقة: hal-02377819; https://normandie-univ.hal.science/hal-02377819Test; https://normandie-univ.hal.science/hal-02377819/documentTest; https://normandie-univ.hal.science/hal-02377819/file/Sefrioui%20BJC%202017.pdfTest

الإتاحة: https://doi.org/10.1038/bjc.2017.250Test
https://normandie-univ.hal.science/hal-02377819Test
https://normandie-univ.hal.science/hal-02377819/documentTest
https://normandie-univ.hal.science/hal-02377819/file/Sefrioui%20BJC%202017.pdfTest

المؤلفون: Emilie Varey, Guillaume Herbreteau, Brigitte Dréno, Audrey Vallée, Anne-Chantal Knol, Sandrine Théoleyre, Gaëlle Quéreux, Amir Khammari, Cécile Frenard, Paul Hofman, Marc G. Denis

المساهمون: Centre hospitalier universitaire de Nantes (CHU Nantes), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre d’Investigation Clinique de Nantes (CIC Nantes), Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre hospitalier universitaire de Nantes (CHU Nantes), Institut de Recherche sur le Cancer et le Vieillissement (IRCAN), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA), Dupuis, Christine

المصدر: Cancers
Cancers, 2020, 12 (7), pp.1871. ⟨10.3390/cancers12071871⟩
Volume 12
Issue 7
Cancers, Vol 12, Iss 1871, p 1871 (2020)

مصطلحات موضوعية: 0301 basic medicine, Neuroblastoma RAS viral oncogene homolog, Oncology, Cancer Research, medicine.medical_specialty, [SDV]Life Sciences [q-bio], NRAS, medicine.disease_cause, lcsh:RC254-282, BRAF, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, medicine, melanoma, Prognostic biomarker, Progression-free survival, Stage (cooking), neoplasms, Univariate analysis, Mutation, business.industry, Melanoma, circulating tumour DNA, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, [SDV] Life Sciences [q-bio], 030104 developmental biology, chemistry, 030220 oncology & carcinogenesis, prognosis, mutation, business, DNA

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11166b621fa6327d9033b4a7dee18e84Test
https://www.hal.inserm.fr/inserm-03683624Test

المؤلفون: Chudasama, D-Y., Aladag, Z., Felicien, M-J., Hall, M., Beeson, J., Asadj, N., Asadi, N., Gidron, Yori, Karteris, E., Anikin, V-B.

المساهمون: Laboratoire Sciences Cognitives et Sciences Affectives - UMR 9193 (SCALab), Université de Lille-Centre National de la Recherche Scientifique (CNRS)

المصدر: ISSN: 1949-2553 ; Oncotarget ; https://hal.univ-lille.fr/hal-04419200Test ; Oncotarget, 2018, Oncotarget, 9 (30), p.21281-21288. ⟨10.18632/oncotarget.25086⟩.

مصطلحات موضوعية: circulating tumour DNA, Alu repeats, DNA integrity index, malignant lung tumours, liquid biopsy, [SCCO]Cognitive science

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/29765538; hal-04419200; https://hal.univ-lille.fr/hal-04419200Test; PUBMED: 29765538

الإتاحة: https://doi.org/10.18632/oncotarget.25086Test
https://hal.univ-lille.fr/hal-04419200Test